IMMUNOGENICITY ASSESSMENT AND CYTOKINE PROFILE IN COVID-19 PATIENTS TREATED WITH HORSE ANTI SARS-Cov-2

MIRANDA S

Congreso; Reunión Anual de Sociedades de BioCiencias. LXVII Reunión Anual de la Sociedad Argentina de Investigaciones Clínicas (SAIC), LXX Reunión Anual de la Sociedad Argentina de Inmunología (SAI) & 3rd French-Argentine Immunology Congress (FAIC).; 2022

SAIC-SAI

This study was approved in 2021 by ANMAT for the evaluation of a product (“P”) -horse Fab´2 anti SARS-Cov-2-, developed by INPB (ANLIS-Malbrán). Patients with COVID diagnosis (n=20) were recruited in Hospital Santojanni to perform a blinded-randomized controlled study comparing iv administration of “P” (T group) at t=0 and t=48hs versus control (C group). Methods: 1)Plasma concentration of “P” was monitored during 28 days with a double antibody ELISA, employing unconjugated and HRP conjugated IgG anti horse and “P” as standard. Plasma “P” concentration was expressed as mg/L. 2)Antibodies anti “P” were evaluated at t=0, 14 and 28 days by an indirect ELISA where a horse IgG pepsin digest was used as antigen coating and anti human IgG-HRP as developer. Samples were loaded at dilutions 1/150 until 1/2400. Titer of anti-equine Fab'2 antibodies was expressed as the average value of the area under the curve OD/log dil. 3)Plasma levels of IL-1β, IL-6, TNFα and IFNα were assessed by a multiplex magnetic bead assay at 96hs and 14 days. Standards were plotted and concentrations determined using xPONENT version 4.2 software and expressed as pg/ml. Results: 1)Samples from the C group were identified due to the lack of circulating horse protein, while “P” was quantified in the T group from t=3hs (